Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Abstract CD20 is an established therapeutic target in B-cell malignancies. The CD20 × CD3 bispecific antibody mosunetuzumab has significant efficacy in B-cell non-Hodgkin lymphomas (NHLs). Because target antigen loss is a recognized mechanism of resistance, we evaluated CD20 expression relative to c...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Stephen J. Schuster, Ling‐Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit Assouline, Nancy L. Bartlett, Lihua E. Budde, Matthew J. Matasar, Hartmut Koeppen, Emily Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, Elicia Penuel
Médium: Artigo
Jazyk:angličtina
Vydáno: 2023
On-line přístup:https://doi.org/10.1182/blood.2023022348
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Internet

https://doi.org/10.1182/blood.2023022348

Podobné jednotky